Pegfilgrastim

培非格司亭

Report date: 2025/05/15 20:00:08

Base Information

Drug NamePegfilgrastim
Drug Alias Name聚乙二醇培非格司亭（Amgen/Kyowa Hakko Kirin）PEG-filgrastim (Amgen/Kyowa Hakko Kirin)Filgrastim SD-01聚乙二醇非格司亭（Amgen/Kyowa Hakko Kirin）聚乙二醇培非拉司亭（Amgen/Kyowa Hakko Kirin） +[20] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsSkin MelanomaDiabetes Mellitus, Type 1Neutropenia +[22] 
Global Approved IndicationsNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2002/01/31
Country/TerritoryCanadaUnited StatesPuerto Rico +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAmgen IncKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiomm SAAmgen Europe BvKyowa Hakko Kirin Co Ltd +[4] 
Inactive CompaniesKyowa Kirin Co LtdOhsu Knight Cancer InstituteUlm University +[8] 
Active IndicationsNeutropeniaBreast Neoplasms
Inactive IndicationsSkin MelanomaDiabetes Mellitus, Type 1Urinary Bladder Neoplasms +[20] 

Other Information

ATC CodeL03AA13
Related LinksWikipediaDrugBankKEGG